Cross-cohort analysis identified an immune checkpoint-based signature to predict the clinical outcomes of neuroblastoma
Sign Up to like & getrecommendations! Published in 2023 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005980
Abstract: Background Neuroblastoma (NB) places a substantial health burden on families worldwide. This study aimed to develop an immune checkpoint-based signature (ICS) based on the expression of immune checkpoints to better assess patient survival risk and… read more here.
Keywords: discovery set; immune checkpoint; based signature; checkpoint based ... See more keywords